Back to search

University of Ioannina

Ανάπτυξη νέων αντιαιμοπεταλιακών παραγόντων και διερεύνηση του μηχανισμού δράσης τους

Abstract

dc:description

The platelet integrin aIIbβ3 plays an important role at the final step of platelet aggregation and that renders it a very promising target in the development of antiplatelet drugs. Upon platelet activation, the integrin extends and switches in its active conformation, where exhibits high affinity for the extracellular ligand. RGD - peptides strongly inhibit the binding of fibrinogen (main ligand) to the receptor and consequently platelet aggregation. However, nowadays the use of aIIbβ3 antagonists in daily clinical have been limited. It has been reported that their ligation to aIIbβ3, has as result the maintenance of the receptor in its active conformation. In this condition, the receptor induce an outside-inside signaling. The development of new aΙΙbβ3 antagonist is necessary. We have previously shown that the 8/peptide YMESRADR corresponding to amino acids 313-320 of the aIIb subunit, acts as a potent inhibitor of platelet aggregation.The purpose of this study is to highlight the mechanism through which YMESRADR exhibits its inhibitory activity effect on platelet aggregation. The results from the in silico modelling analysis of the receptor - 8/peptide interaction, showed that the peptide is able to act as a substitute for the βribbon by forming a clasp restraining the β3 hybrid and βI domains in a closed conformation. The proposed interactions involve: D319 (8/peptide) - K384 (β3), R320 (8/peptide) - E356 (β3) και Y313 (8/peptide) και E297 (β3).The residues that were found to take place at the interaction, were confirmed by studies of CHO cells (expressing the wild type or mutated aIIbβ3 integrin) adhesion to fibrinogen under flow conditions and inhibitory studies on platelet functions of the native or Ala substituted peptides.In order to confirm the role of the Y313 and R320 amino acid residues in the interaction with the receptor and moreover to develop new potent inhibitors of platelet aggregation, 14 aIIb derived peptides were designed, synthesized, purified, identified and tested for their inhibitory effect. The results indicated that YMESRADR exerts its inhibitory effect on fibrinogen binding through its interaction with the βI and hybrid domains of β3 subunit; maintaining the receptor in its low affinity state. This study confirms the crucial role of the D319 and R320 amino acids on peptide’s inhibitory activity. On the other hand, contribution of Y313 does not seem to be crucial. The inhibitory activity of RMESRADR peptide reinforces this point of view, wherein besides of arginine hydrogen-bonding capability, ionic interactions are possible to be developed.In conclusion, this study revealed that a new antiplatelet approach can be used for developing allosteric aIIbβ3 antagonists. These antagonists could act via their interaction with the receptor maintaining it in its low affinity state.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Trypou, Paraskevi
  • Τρύπου, Παρασκευή

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35966

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Trypou, Paraskevi; Τρύπου, Παρασκευή. Ανάπτυξη νέων αντιαιμοπεταλιακών παραγόντων και διερεύνηση του μηχανισμού δράσης τους. University of Ioannina, 2015. http://hdl.handle.net/10442/hedi/35966